SAN DIEGO, May 14, 2019 /PRNewswire/ -- Evofem
Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage
biopharmaceutical company, announced today that its Chief Executive
Officer, Saundra Pelletier, will
present at the 2019 RBC Capital Markets Global Healthcare
Conference on Wednesday, May 22, 2019
at 10:30 AM EDT. The conference
will be held at the InterContinental New York Barclay Hotel in
New York, NY.
To access the live and archived webcasts of the presentation,
visit the Investors section of the Evofem Biosciences website at
www.evofem.com. The webcast will be archived on the Evofem
website for 90 days following the event.
About Evofem Biosciences
Evofem Biosciences, Inc., is
a clinical-stage biopharmaceutical company committed to developing
and commercializing innovative products to address unmet needs in
women's sexual and reproductive health. Evofem Biosciences aims to
advance the lives of women by developing innovative solutions, such
as woman-controlled contraception and potential protection from
certain sexually transmitted infections ("STIs"). The Company
is leveraging its proprietary Multipurpose Vaginal pH Regulator™
(MVP-R) platform to develop Amphora® (L-lactic acid, citric acid
and potassium bitartrate) for birth control and prevention of
urogenital acquisition of certain STIs. For more information,
please visit www.evofem.com.
About Amphora
Amphora is an MVP-R designed to regulate
vaginal pH within the normal range of 3.5 to 4.5. This maintains an
acidic environment which is inhospitable to sperm as well as
certain viral and bacterial pathogens associated with sexually
transmitted infections but is integral to the survival of healthy
bacteria in the vagina. Amphora met the pre-specified primary
endpoint of AMPOWER, the Phase 3 clinical trial evaluating this
MVP-R for the prevention of pregnancy in approximately 1,400 women
at 112 centers in the United
States. Amphora had a favorable safety profile, and was well
tolerated. The Company plans to re-submit the Amphora New Drug
Application (NDA) in the fourth quarter of 2019.
The Company recently completed patient enrollment in AMPREVENCE,
a double-blinded placebo-controlled Phase 2b clinical trial of Amphora to prevent
urogenital acquisition of Chlamydia trachomatis (primary
endpoint) and Neisseria gonorrhea (secondary endpoint) in
women. This study enrolled approximately 850 women at approximately
50 centers in the United States.
Top-line data is expected in the fourth quarter of 2019.
Amphora® is a registered trademark and Multipurpose Vaginal
pH Regulator™ is a trademark of Evofem Biosciences, Inc.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including statements related to the timing of the planned NDA
Amphora resubmission for prevention of pregnancy, potential FDA
approval of Amphora, and the potential commercial launch of
Amphora, the anticipated results of the Phase 2b clinical
trial of Amphora to prevent urogenital acquisition
of Chlamydia trachomatis and Neisseria
gonorrhea in women, and any expected completion date or
general timing for this clinical trial. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from those, express or implied, in
these forward-looking statements. Important factors that could
impair the value of Evofem Biosciences' assets and business are
disclosed in the risk factors contained in its Annual Report on
Form 10-K filed with the Securities and Exchange
Commission and subsequent filings. All forward-looking
statements are expressly qualified in their entirety by such
factors. Evofem Biosciences does not undertake any duty to update
any forward-looking statement except as required by law.
Investor Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
O: (858) 550-1900 x167
M: (917) 673-5775
Media Contact
Greg
Jawski
Porter Novelli
Greg.jawski@porternovelli.com
M: (917) 749-4964
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-2019-rbc-capital-markets-global-healthcare-conference-300849420.html
SOURCE Evofem Biosciences, Inc.